German biotech calls for tax reforms following EC blocking of MoRaKG

16 October 2009

The European Commission has blocked parts of a German law known as MoRaKG, the legislation on the modernization of the legal framework for venture capital and private equity investments.

The MoRaKG would have seen venture capital firms receive some tax breaks and was designed to temper the heavy burden of the 2008 corporate tax reform on small- and medium-sized enterprises (SMEs). Thanks to the withholding tax and stricter rules on carrying forward tax losses, the 2008 reform put SMEs, which require more investment, at a disadvantage against big corporations.

'The decision of the Commission shows that last year's corporate tax reform has nothing to offer us,' said Peter Heinrich, chairman of the country's biotechnology trade group the Biodeutschland. He is urging the new government to start anew and rescind all parts of the corporate tax reform that undermine SMEs.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight





More Features in Biotechnology